Scalper1 News
Speculation about the newest class of cholesterol drugs heated up Friday after the FDA released briefing documents for Tuesday’s advisory committee meeting on Praluent, the PCSK9 inhibitor from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY). Nevertheless, Regeneron stock rose to an all-time high Friday for the second straight day. The documents framed the issues to ponder when the panel votes on whether to recommend approving the drug, advice Scalper1 News
Scalper1 News